Ultrasound-mediated gene delivery (UMGD) is a non-invasive gene transfer technique, utilizing high power ultrasound and DNA-bearing microbubbles. Despite modest transfection efficiency, its high organ, tissue specificity and repeatability make it an attractive therapeutic option. UMGD has been used in a variety of in vivo applications, including cardiac and skeletal muscle, kidney, liver, cerebral and even lung, and have been studied using many gene vectors, including plasmid, viral and small interfering RNA. This presentation will focus specifically on cardiac applications using plasmid DNA, including 1) introduction of UMGD in the heart, including optimization of parameters and protocols, 2) UMGD for therapeutic angiogenesis in chronic ischemia, including multi pro-angiogenic gene therapy and combination gene-and progenitor cell-based therapies for chronic hindlimb ischemia, and 3) applications for anti-apoptotic therapy in heart failure and ischemia-reperfusion injury.
INTRODUCTION
Over the past three decades, there has been a substantial increase in our knowledge and understanding of the molecular and cellular perturbations that characterize many cardiovascular diseases. Importantly this has resulted in new therapeutic approaches that specifically target molecular entities that are involved in the pathogenesis of heart disease. One such novel approach involves in vivo cardiac transfection or gene therapy, whereby expression of a transgene can modulate selective molecular and cellular targets. Despite a wealth of pre-clinical data, the initial promise of gene transfer to treat advanced cardiovascular diseases has not been met. The largely disappointing results of clinical trials to date are related to many factors, including 1) lack of efficacy of single therapeutic targets, 2) single treatment/dose, and 3) suboptimal vectors and delivery techniques.
Ultrasound-mediated gene delivery (UMGD) is a non-invasive method of gene delivery that can be applied to cardiovascular diseases. Gene products are incorporated within microbubbles, attached to the bubble surface or administered along with free flowing microbubbles intravenously, where they traverse the systemic circulation. By applying high power ultrasound over the target tissue or organ, microbubbles undergo cavitation effects in the presence of gene products, resulting in deposition and targeted tissue transfection. This paper will review cardiovascular applications of UMGD including basic principles, parameters and protocols, and specific applications for ischemic cardiac and vascular disease, heart failure and ischemia-reperfusion injury.
PARAMETERS AND PROTOCOLS
Microbubble carrier agents are composed of a gas-filled core (nitrogen or other inert gas) with an outer shell (lipid, synthetic biopolymer, albumin). With a mean diameter of 1-3 µm, these microbubbles have similar properties as red blood cells, and are able to freely circulate through the pulmonary and systemic microcirculation after an intravenous injection (1). For UMGD, microbubbles and DNA are typically administered as a slow continuous infusion that allows a stable concentration within the blood during external ultrasound application. At high acoustic power, non-linear vibrations of the microbubbles at their resonant frequency eventually leads to the destruction of the microbubbles, the resultant bioeffects producing transfection via several mechanisms, including microporation, sonoporation and endocytosis (2, 3) . Three methods for gene-microbubble delivery have been used for UMGD -1) microbubbles generated with the genes incorporated into the shell, 2) charge-coupling or attachment after microbubble generation, and 3) passive co-administration of DNA with free microbubbles. Out of these three methods, my lab has the greatest experience with charge-coupling. The negatively charged plasmid DNA is chargecoupled, with studies demonstrating approximately 6700 plasmids attached to each cationic microbubble (2).
For UMGD, the microbubble-DNA complex or suspension is given intravenously as a slow bolus or continuous infusion. Due to limited ultrasound beam width, the ultrasound transducer is usually scanned across the target organ or tissue to maximize delivery. Studies have shown that in order to maximize gene transfection, parameters should be set for 1) triggered ultrasound at set intervals, 3) lower transmit frequency, and 3) greater acoustic power (4) . UMGD of the heart, transgene expression is higher in the anterior as compared to the posterior wall due to the proximity of the anterior wall to the ultrasound probe and attenuation of the posterior wall from the high microbubble concentration in the ventricular cavity (4).
CARDIOVASCULAR THERAPEUTIC APPLICATIONS OF UMGD: REVIEW
Many therapeutic applications of UMGD have been studied in pre-clinical animal models of cardiovascular disease. Table 1 lists the published studies of UMGD for therapy of cardiac diseases, and Table 2 lists studies for targeted therapy of vascular diseases. 
CARDIOVASCULAR THERAPEUTIC APPLICATIONS OF UMGD: RECENT UPDATE
Most recently, my lab has begun exploring UMGD for therapeutic applications in heart failure and in the setting of ischemia reperfusion injury. Paul Lee studied UMGD of survivin (SURV), an inhibitor of apoptosis protein, to prevent apoptosis and attenuate left ventricular (LV) systolic dysfunction in a model of heart failure induced by doxorubicin (DOX) in rats. He showed that survivin gene therapy by UMGD resulted in reduced cardiomyocyte apoptosis, less interstitial fibrosis, and attenuation of LV systolic dysfunction, as compared to control untreated animals and animals treated with UMGD of empty plasmid. Azadeh Mofid studied UMGD of S100A6, a member of EF-hand Ca 2+ -binding proteins in the setting of ischemia-reperfusion injury in rats. She demonstrated that overexpression of S100A6 prevents cardiomyocyte apoptosis after ischemia-reperfusion injury, attenuation of adverse LV remodeling and improved LV function, as compared to control untreated rats. These promising results show the potential of UMGD for cardiac therapeutic applications.
